Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Karyopharm Therapeutics Affirms FY2025 Sales Guidance of $140.000M-$155.000M vs $149.328M Est

Author: Benzinga Newsdesk | November 03, 2025 08:01am
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2025 sales outlook from $140.000 million-$155.000 million to $140.000 million-$155.000 million vs $149.328 million estimate.

Posted In: KPTI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist